Contents
pdf Download PDF pdf Download XML
667 Views
693 Downloads
Share this article
Research Article | Volume 16 Issue 2 (None, 2023) | Pages 29 - 31
Rapid clearance of erythrodermic psoriasis with apremilast
 ,
 ,
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC5776028
Received
May 19, 2017
Published
Dec. 1, 2017
Abstract

Background:Apremilast is a new immunomodulatory drug, a small molecule inhibitor of PDE4, which down-regulates the expression of multiple pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin 17, interleukin 23. Main observations:We describe a case of a 54-year-old man with erythroderma in the course of psoriasis (PASI=49), with contraindications to other psoriasis therapies, in whom total clearance of skin lesions was achieved by day 20 after therapy with apremilast at a dose of 30 mg bid (ΔPASI = 100). The patient had a history of prior use of cyclosporine, methotrexate and adalimumab. His comorbidities included obesity, fatty liver and hypercholesterolemia.Conclusion:In this case of erythroderma in the course of psoriasis apremilast led to total clearance of all cutaneous lesions.

Keywords
Recommended Articles
Research Article
Successful Management of Severe Pediatric Annular Psoriasis with Targeted IL-17 Inhibition using Ixekizumab: A Case Report
...
Published: 20/11/2026
Research Article
A study on incidence and prognosis of Hyponatremia among patients admitted in High dependency respiratory care unit
Published: 08/01/2022
Research Article
Metabolic Syndrome Among Patients with Chronic Obstructive Pulmonary Disease: A prospective observational Study
Published: 24/06/2022
Research Article
A recurrent ulcer over the left thigh: The Diagnostic Mimicry between lupus profundus and non-uremic calciphylaxis
...
Published: 26/10/2026
© Copyright Spejalisci Dermatolodzy